New Once-Daily painkiller could reduce opioid use after surgery
NCT ID NCT06423703
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested a new drug called cebranopadol (TRN-228) for moderate to severe acute pain after bunionectomy. 240 participants received either cebranopadol once daily, oxycodone four times daily, or placebo for three days. The study measured pain relief and whether patients needed extra opioid rescue medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cebranopadol (also called TRN-228)
What this could lead to
If successful, cebranopadol could provide a new once-daily option for managing acute pain after surgery, potentially reducing the need for opioid rescue medication.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo or existing treatments, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALLEVIATE 2 Site 001101
Salt Lake City, Utah, 84107, United States
-
ALLEVIATE 2 Site 001102
Atlanta, Georgia, 30331, United States
-
ALLEVIATE 2 Site 001103
Tampa, Florida, 33613, United States
-
ALLEVIATE 2 Site 001104
McAllen, Texas, 78501, United States
-
ALLEVIATE 2 Site 001105
Pasadena, Maryland, 21122, United States
-
ALLEVIATE 2 Site 001106
Little Rock, Arkansas, 72211, United States
-
ALLEVIATE 2 Site 001107
Overland Park, Kansas, 66212, United States
-
ALLEVIATE 2 Site 001108
Sheffield, Alabama, 35660, United States
-
ALLEVIATE 2 Site 001111
San Antonio, Texas, 78240, United States
-
Alleviate 2 001113
Houston, Texas, 77043, United States